KOSP Kos Pharmaceuticals

Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that Adrian Adams, President and Chief Executive Officer, will present at the SG Cowen 26th Annual Health Care Conference which is being held March 6 - March 9, 2006 in Boston, Massachusetts. Kos' presentation will take place at 2:20 pm ET on Monday, March 6, 2006. Interested parties can access the webcast information by going to the investor relations section of Kos' website at www.kospharm.com, and referencing upcoming events. About Kos Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos' strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for the treatment of hypertension and angina, and Teveten(R) and Teveten(R)HCT for the treatment of hypertension. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future.